Ka-Lok Ng

Dr. Ka-Lok Ng

Asia University, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
PDF file
KNKa-Lok Ng
Ka-Lok Ng
JCJin-Shuei Ciou
Jin-Shuei Ciou
CHChien-Hung Huang
Chien-Hung Huang

21 January 2015 in BMC Systems Biology
Verified
Journal Article
Open access
PDF file
Wen-Tsong HsiehWen-Tsong Hsieh
Wen-Tsong Hsieh
KTKe-Rung Tzeng
Ke-Rung Tzeng
JCJin-Shuei Ciou
Jin-Shuei Ciou
JTJeffrey Jp Tsai
Jeffrey Jp Tsai
NKNilubon Kurubanjerdjit
Nilubon Kurubanjerdjit
KNKa-Lok Ng
Ka-Lok Ng
Molecular networks are the basis of biological processes. Such networks can be decomposed into smaller modules, also known as network motifs. These motifs show interesting dynamical behaviors, in which co-operativity effects between the motif components play a critical role in human diseases. We have developed a motif-searching algorithm, which is able to identify common motif types from the cancer networks and signal transduction networks (STNs). Some of the network motifs are interconnected which can be merged together and form more complex structures, the so-called coupled motif structures (CMS). These structures exhibit mixed dynamical behavior, which may lead biological organisms to perform specific functions.

11 January 2016 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
CHChien-Hung Huang
Chien-Hung Huang
MCMu-Hsin Mu-Hsin Chang
Mu-Hsin Mu-Hsin Chang
CHChia-Wei Hsu
Chia-Wei Hsu
Chi-Ying F. HuangChi-Ying F. Huang
Chi-Ying F. Huang
KNKa-Lok Ng
Ka-Lok Ng
Non-small cell lung cancer (NSCLC) is one of the leading causes of death globally, and research into NSCLC has been accumulating steadily over several years. Drug repositioning is the current trend in the pharmaceutical industry for identifying potential new uses for existing drugs and accelerating the development process of drugs, as well as reducing side effects. This work integrates two approaches - machine learning algorithms and topological parameter-based classification - to develop a novel pipeline of drug repositioning to analyze four lung cancer microarray datasets, enriched biological processes, potential therapeutic drugs and targeted genes for NSCLC treatments. A total of 7 (8) and 11 (12) promising drugs (targeted genes) were discovered for treating early- and late-stage NSCLC, respectively. The effectiveness of these drugs is supported by the literature, experimentally determined in-vitro IC50 and clinical trials. This work provides better drug prediction accuracy than competitive research according to IC50 measurements. With the novel pipeline of drug repositioning, the discovery of enriched pathways and potential drugs related to NSCLC can provide insight into the key regulators of tumorigenesis and the treatment of NSCLC. Based on the verified effectiveness of the targeted drugs predicted by this pipeline, we suggest that our drug-finding pipeline is effective for repositioning drugs.

29 March 2022 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
ASAmbily Sivadas
Ambily Sivadas
Victor KokVictor Kok
Victor Kok
KNKa-Lok Ng
Ka-Lok Ng

1 January 2014 in BMC Systems Biology
Verified
Journal Article
Open access
PDF file
CWCharles C.N. Wang
Charles C.N. Wang
PCPei-Chun Chang
Pei-Chun Chang
KNKa-Lok Ng
Ka-Lok Ng
CCChun-Ming Chang
Chun-Ming Chang
Phillip SheuPhillip Sheu
Phillip Sheu
JTJeffrey Jp Tsai
Jeffrey Jp Tsai
Several dynamic models of a gene regulatory network of the light-induced floral transition process in Arabidopsis have been developed to capture the behavior of gene transcription and infer predictions based on experimental observations. It has been proven that the models can make accurate and novel predictions, which generate testable hypotheses.

25 May 2021 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
EDEskezeia Y. Dessie
Eskezeia Y. Dessie
JTJeffrey J. P. Tsai
Jeffrey J. P. Tsai
JCJan-Gowth Chang
Jan-Gowth Chang
KNKa-Lok Ng
Ka-Lok Ng
Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal carcinoma and patients at advanced stage showed poor survival rate. Despite microRNAs (miRNAs) are used as potential biomarkers in many cancers, miRNA biomarkers for predicting the tumor stage of ccRCC are still limitedly identified. Therefore, we proposed a new integrated machine learning (ML) strategy to identify a novel miRNA signature related to tumor stage and prognosis of ccRCC patients using miRNA expression profiles. A multivariate Cox regression model with three hybrid penalties including Least absolute shrinkage and selection operator (Lasso), Adaptive lasso and Elastic net algorithms was used to screen relevant prognostic related miRNAs. The best subset regression (BSR) model was used to identify optimal prognostic model. Five ML algorithms were used to develop stage classification models. The biological significance of the miRNA signature was analyzed by utilizing DIANA-mirPath. Results: A four-miRNA signature associated with survival was identified and the expression of this signature was strongly correlated with high risk patients. The high risk patients had unfavorable overall survival compared with the low risk group (HR = 4.523, P-value = 2.86e−08). Univariate and multivariate analyses confirmed independent and translational value of this predictive model. A combined ML algorithm identified six miRNA signatures for cancer staging prediction. After using the data balancing algorithm SMOTE, the Support Vector Machine (SVM) algorithm achieved the best classification performance (accuracy = 0.923, sensitivity = 0.927, specificity = 0.919, MCC = 0.843) when compared with other classifiers. Furthermore, enrichment analysis indicated that the identified miRNA signature involved in cancer-associated pathways. Conclusions: A novel miRNA classification model using the identified prognostic and tumor stage associated miRNA signature will be useful for risk and stage stratification for clinical practice, and the identified miRNA signature can provide promising insight to understand the progression mechanism of ccRCC.